EUVIMEDEUVIMED entdecken
Vergleichsstudie

Cost evaluation of continuation of therapy with dalbavancin compared to standard-of-care antibiotics alone in hospitalized persons who inject drugs with severe gram-positive infections

Devin Donnelly, Kelly E Pillinger, Ashita Debnath, William DePasquale, Sonal Munsiff, Ted Louie, Courtney Marie Cora Jones, Stephanie Shulder

American Journal of Health-System Pharmacy · 2024

DOI: 10.1093/ajhp/zxae025 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift American Journal of Health-System Pharmacy, 2024. Verfasst von Devin Donnelly und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Rochester Medical Center: Strong Memorial Hospital, Rochester, NY, USA. Hauptthemen laut MEDLINE: Teicoplanin, Anti-Bacterial Agents, Hospitalization, Gram-Positive Bacterial Infections. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Persons who inject drugs (PWID) are at risk for severe gram-positive infections and may require prolonged hospitalization and intravenous (IV) antibiotic therapy. Dalbavancin (DBV) is a long-acting lipoglycopeptide that may reduce costs and provide effective treatment in this population.

Methods

This was a retrospective review of PWID with severe gram-positive infections. Patients admitted from January 1, 2017, to November 1, 2019 (standard-of-care [SOC] group) and from November 15, 2019, to March 31, 2022 (DBV group) were included. The primary outcome was the total cost to the healthcare system. Secondary outcomes included hospital days saved and treatment failure.

Results

A total of 87 patients were included (37 in the DBV group and 50 in the SOC group). Patients were a median of 34 years old and were predominantly Caucasian (82%). Staphylococcus aureus (82%) was the most common organism, and bacteremia (71%) was the most common type of infection. Compared to the SOC group, the DBV group would have had a median of 14 additional days of hospitalization if they had stayed to complete their therapy (P = 0.014). The median total cost to the healthcare system was significantly lower in the DBV group than in the SOC group ($31,698.00 vs $45,093.50; P = 0.035). The rate of treatment failure was similar between the groups (32.4% in the DBV group vs 36% in the SOC group; P = 0.729).

Conclusion

DBV is a cost-saving alternative to SOC IV antibiotics for severe gram-positive infections in PWID, with similar treatment outcomes. Larger prospective studies, including other patient populations, may demonstrate additional benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TeicoplaninAnti-Bacterial AgentsHospitalizationGram-Positive Bacterial InfectionsHumansRetrospective StudiesMaleFemaleAdultMiddle AgedSubstance Abuse, IntravenousLength of StayStandard of CareSeverity of Illness IndexYoung Adult

Stichwörter der Autor:innen

cost evaluationdalbavancingram positivelipoglycopeptidepersons who inject drugs

Substanzen

TeicoplanindalbavancinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pharmacy, University of Rochester Medical Center: Strong Memorial Hospital, Rochester, NY, USA.
  • PRIME Education, LLC, New York, NY, USA.
  • Community Medical Center, Toms River, NJ, USA.
  • Department of Pharmacy, University of Rochester Medical Center: Highland Hospital, Rochester, NY, USA.
  • Division of Infectious Diseases, University of Rochester Medical Center: Strong Memorial Hospital, Rochester, NY, USA.
  • Department of Emergency Medicine, University of Rochester Medical Center: Strong Memorial Hospital, Rochester, NY, USA.

Zitieren

APA

Donnelly, D., Pillinger, K. E., Debnath, A., DePasquale, W., Munsiff, S., Louie, T., Jones, C. M. C., & Shulder, S. (2024). Cost evaluation of continuation of therapy with dalbavancin compared to standard-of-care antibiotics alone in hospitalized persons who inject drugs with severe gram-positive infections. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxae025

Vancouver

Donnelly D, Pillinger KE, Debnath A, DePasquale W, Munsiff S, Louie T, et al. Cost evaluation of continuation of therapy with dalbavancin compared to standard-of-care antibiotics alone in hospitalized persons who inject drugs with severe gram-positive infections. American Journal of Health-System Pharmacy. 2024. doi:10.1093/ajhp/zxae025

BibTeX
@article{Donnelly2024,
  author = {Donnelly, Devin and Pillinger, Kelly E and Debnath, Ashita and DePasquale, William and Munsiff, Sonal and Louie, Ted and Jones, Courtney Marie Cora and Shulder, Stephanie},
  title = {Cost evaluation of continuation of therapy with dalbavancin compared to standard-of-care antibiotics alone in hospitalized persons who inject drugs with severe gram-positive infections},
  journal = {American Journal of Health-System Pharmacy},
  year = {2024},
  doi = {10.1093/ajhp/zxae025}
}
Kostenlos starten →